These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36049581)

  • 1. Recent advances in HDAC-targeted imaging probes for cancer detection.
    Tang C; Wang X; Jin Y; Wang F
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188788. PubMed ID: 36049581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC Inhibitors: Innovative Strategies for Their Design and Applications.
    Daśko M; de Pascual-Teresa B; Ortín I; Ramos A
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDACs as an emerging target in endocrine tumors: a comprehensive review.
    Klieser E; Neumayer B; Di Fazio P; Mayr C; Neureiter D; Kiesslich T
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):143-154. PubMed ID: 36872882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of histone deacetylases in cancer.
    Montezuma D; Henrique RM; Jerónimo C
    Crit Rev Oncog; 2015; 20(1-2):19-34. PubMed ID: 25746102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting histone deacetylases for heart diseases.
    Jin G; Wang K; Zhao Y; Yuan S; He Z; Zhang J
    Bioorg Chem; 2023 Sep; 138():106601. PubMed ID: 37224740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
    Falkenberg KJ; Johnstone RW
    Nat Rev Drug Discov; 2014 Sep; 13(9):673-91. PubMed ID: 25131830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability.
    Milazzo G; Mercatelli D; Di Muzio G; Triboli L; De Rosa P; Perini G; Giorgi FM
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32429325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.
    Marks PA
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1049-66. PubMed ID: 20687783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential molecular mechanistic behavior of HDACs in cancer progression.
    Singh T; Kaur P; Singh P; Singh S; Munshi A
    Med Oncol; 2022 Aug; 39(11):171. PubMed ID: 35972597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
    Beumer JH; Tawbi H
    Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An HDAC-Targeted Imaging Probe LBH589-Cy5.5 for Tumor Detection and Therapy Evaluation.
    Meng Q; Liu Z; Li F; Ma J; Wang H; Huan Y; Li Z
    Mol Pharm; 2015 Jul; 12(7):2469-76. PubMed ID: 26030093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Fluorescent Probes for Detecting HDAC Activity.
    Tan S; Li X
    Chem Asian J; 2022 Nov; 17(22):e202200835. PubMed ID: 36117388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of HDACs in normal and malignant hematopoiesis.
    Wang P; Wang Z; Liu J
    Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present).
    Liu YM; Liou JP
    Expert Opin Ther Pat; 2023; 33(5):349-369. PubMed ID: 37249104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.